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Abstract
Background: Angiotensin I-converting enzyme (ACE) metabolizes a range of peptidic substrates and plays a key role in
blood pressure regulation and vascular remodeling. Thus, elevated ACE levels may be associated with an increased risk for
different cardiovascular or respiratory diseases. Previously, a striking familial elevation in blood ACE was explained by
mutations in the ACE juxtamembrane region that enhanced the cleavage-secretion process. Recently, we found a family
whose affected members had a 6-fold increase in blood ACE and a Tyr465Asp (Y465D) substitution, distal to the stalk region,
in the N domain of ACE.
Methodology/Principal Findings: HEK and CHO cells expressing mutant (Tyr465Asp) ACE demonstrate a 3- and 8-fold
increase, respectively, in the rate of ACE shedding compared to wild-type ACE. Conformational fingerprinting of mutant ACE
demonstrated dramatic changes in ACE conformation in several different epitopes of ACE. Cell ELISA carried out on CHO-
ACE cells also demonstrated significant changes in local ACE conformation, particularly proximal to the stalk region.
However, the cleavage site of the mutant ACE - between Arg1203 and Ser1204 - was the same as that of WT ACE. The Y465D
substitution is localized in the interface of the N-domain dimer (from the crystal structure) and abolishes a hydrogen bond
between Tyr465 in one monomer and Asp462 in another.
Conclusions/Significance: The Y465D substitution results in dramatic increase in the rate of ACE shedding and is associated
with significant local conformational changes in ACE. These changes could result in increased ACE dimerization and
accessibility of the stalk region or the entire sACE, thus increasing the rate of cleavage by the putative ACE secretase
(sheddase).
Citation: Danilov SM, Gordon K, Nesterovitch AB, Lu ¨nsdorf H, Chen Z, et al. (2011) An Angiotensin I-Converting Enzyme Mutation (Y465D) Causes a Dramatic
Increase in Blood ACE via Accelerated ACE Shedding. PLoS ONE 6(10): e25952. doi:10.1371/journal.pone.0025952
Editor: Pieter H. Reitsma, Leiden University Medical Center, The Netherlands
Received May 12, 2011; Accepted September 14, 2011; Published October 5, 2011
Copyright:  2011 Danilov et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Partial funding was provided by South African National Research Foundation, the German Academic Exchange. Molecular graphics images were
produced using the University of California San Francisco Chimera package from the Resource for Biocomputing, Visualization, and Informatics at the University of
California, San Francisco (supported by National Institutes of Health P41 RR001081). The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: danilov@uic.edu
. These authors contributed equally to this work.
Introduction
Angiotensin I-converting enzyme (ACE, CD143) is a Zn
2+
dipeptidyl carboxydipeptidase which plays a key role in the
regulation of blood pressure and in the development of vascular
pathology and remodeling [1–4]. ACE is constitutively expressed
on the surface of endothelial cells, different absorptive epithelial
and neuroepithelial cells [5–13], and cells of the immune system
(macrophages, dendritic cells) [14–16]. Somatic ACE (ACE)
contains two catalytic centers in the N- and C-terminal
ectodomains [17]. ACE was assigned as a common differentiation
marker - CD143 [11,18].
Besides membrane-bound forms of ACE, blood and other
biological fluids contain a variable amount of soluble ACE. Serum
ACE most likely originates from endothelial cells [19], mostly from
lung – due to preferential ACE expression in lung capillaries
[11,13,20] - by proteolytic cleavage [21–22]. Soluble ACE from
CHO cells transfected with human ACE cDNA and porcine ACE
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peptide bond in a stalk region near the transmembrane domain
[23]. The cleavage/secretion process is catalyzed by an uniden-
tified membrane-bound ACE secretase [24]. In healthy individ-
uals, the level of ACE in the blood is very stable [25], whereas
granulomatous diseases (sarcoidosis in particular) and Gaucher’s
disease lead to a significant increase of ACE activity in the blood
[26–28]. Serial serum ACE measurements now are an essential
tool for the diagnosis and monitoring the clinical course of
sarcoidosis [29–31].
A mutation in the stalk region of ACE – Pro1199Leu [32–33] –
explained a dramatic (5-fold) increase in ACE activity in the blood
of affected individuals from Holland [32], Germany [34], and the
USA [35]. Despite the fact that people with this mutation exhibit
no clinical abnormalities [32], testing for this mutation is of
considerable clinical importance. For example, failure to appre-
ciate that elevation of ACE levels is genetically determined in an
affected individual may lead to false diagnosis of neurosarcoidosis
and consequently to unnecessary long-term immunosuppressive
treatment [34] or diagnostic procedures [36]. Another mutation in
the stalk region that introduced a premature termination codon
(Trp1197Stop) led to direct secretion of mutant ACE into the
circulation and consequently a 14-fold increase in blood ACE
[37].
Here we report the identification of a new mutation in ACE,
substitution of Tyr in position 465 in the N domain to Asp
(Y465D), which is distal to the stalk region, where proteolytic
cleavage occurs, and leads to significant increase in the rate of
ACE shedding. This mutation occurs in the interface of an N-
domain dimer observed during crystallization of the N domain of
ACE [38]. Moreover, the Y465D substitution results in significant
local conformational changes in ACE. Therefore, it is likely that
the Y465D mutation affects the extent of ACE dimerization and
increases the accessibility of either the stalk region for cleavage or a
secondary binding site/recognition domain of ACE, thus con-
firming our hypothesis of a link between ACE dimerization and
shedding [39–40].
Materials and Methods
Site-directed mutagenesis and in vitro analysis of the
mutant ACEs
cDNAs encoding mutant ACE protein were created by
GenScript (Piscataway, NJ) by mutation of the GAT codon
(Tyr) at position 465 (mature somatic ACE numbering [17]) to
codon TAT that encodes an Asp in the expression vector based on
pcDNA3.1+/Hygro (Invitrogen Corp., Carlsbad, CA), which
contains full-length sACE cDNA controlled by a CMV promoter
[41]. Plasmid DNA was sequenced and clones with the desired
mutation were selected for each mutation.
Plasmids carrying the cDNA for wild-type (WT) ACE and
above mutant were stably expressed in Human Embryonic Kidney
(HEK) cells (ATCC, Manassas, VA) using Plus Reagent (Invitro-
gen Corp., Carlsbad, CA). Culture medium (Ultra-CHO medium,
Cambrex Bio-Science, Walkersville, MD or serum-free MEM)
from these cells was used as a source of the secreted (soluble) ACE
(WT and mutant) for biochemical and immunological character-
ization. Lysate of these cells obtained with detergent Triton X-100
(0.5% in PBS) was used as a source of membrane-bound form of
WT and mutant ACE. Cells at confluence (CHO or HEK) were
washed twice with PBS. Triton X-100 (final concentration 0.5% in
50 mM Tris-HCl, pH 7.5 containing 150 mM NaCl) and
protease inhibitor cocktail (without EDTA) were added to the
cells (1 ml per 60 mm petri dish). After 30 minutes incubation at
4uC, cells were scraped and the whole lysate was centrifuged at
10 000 g to remove cell debris. The supernatant was used as cell
lysate. The rate of ACE shedding was determined as the ratio of
ACE activity in the culture medium to the sum of ACE activity in
the medium and the lysate.
Chinese Hamster Ovary (CHO) cells (ATCC, Manassas, VA)
were stably transfected with cDNA coding mutant ACE using the
Ca2PO4 method (Profection Mammalian Transfection System,
Promega, Madison, WI). After transfection, cells were grown to
confluency in enriched medium [50% Dulbecco’s Modified Eagle
Medium (DMEM) 50% HAMS-F12 supplemented with 10% fetal
calf serum (FCS) and 20 mM HEPES buffer with 400 mg/ml
hygromycin (all reagents are from Sigma-Aldrich, St. Louis, MO).
Then, cells were lifted and sorted for high expressing cells by flow
cytometry, using the N domain-specific anti-ACE mAb 5C5,
having the same epitope specificity as mAb i2H5 [42]. Cells were
then serum starved overnight in minimal medium [50% DMEM,
50% HAMS-F12, 2% FCS, 20 mM HEPES buffer, 100 U/ml
penicillin and 100 mg/ml streptomycin], and the medium assayed
for ACE activity.
ACE activity assay
ACE activity in culture medium (soluble ACE) or lysates of
ACE-expressing cells (membrane-bound form) was measured
using a fluorimetric assay with two ACE substrates - 2 mM Z-
Phe-His-Leu [43] or 5 mM Hip-His-Leu [44]. Briefly, 20–40 ml
aliquots of culture medium or lysates (diluted 1/5 in PBS-BSA
(0.1 mg/ml), were added to 200 ml of ACE substrate and
incubated for the appropriate time at 37uC. The His-Leu product
was quantified fluorimetrically.
Western blot analysis of mutant ACEs
Samples from HEK cells expressing sACE for SDS electropho-
resis were equilibrated to a final ACE activity of 5 mU/ml (Hip-
His-Leu as a substrate) and were run using 7.5% Tris-HCl pre-cast
SDS-PAGE gels (Bio-Red Laboratories, Hercules, CA). After
electrophoretic transfer of proteins to microporous PVDF-Plus
membranes, each membrane was incubated in 10 mM Tris-HCl
(pH 8.0) buffer containing 150 mM NaCl, 0.05% Tween 20, and
5% dry milk prior to incubation overnight at 4uC with mouse
mAbs to sequential epitopes on human ACE, suitable for detection
of the denatured ACE - 3C5, 1D8, 5C8 [45–47]. Subsequent
steps were carried out with the biotin/streptavidin system
(Amresco, Solon, OH) and peroxidase activity was developed
using WestPico Super Signal Chemiluminescense substrate
(Pierce, Rockford, IL).
Samples from CHO cells expressing sACE were separated by
SDS-PAGE using the Mini PROTEAN
TM III system (BIO-RAD,
Hercules, CA) with 6% resolving and 3% stacking gels in a Tris-
glycine tank buffer (pH 8.3). Protein was transferred to Hybond
ECL nitrocellulose membrane (GE Healthcare LifeSciences,
Buckinghamshire, UK) in transfer buffer (20 mM Tris-base,
150 mM glycine, 20% methanol) using the Mini PROTEANTM
III system. For detection of protein, membranes were incubated in
blocking buffer (Tris-buffered saline, 0.1% tween-20, 5% skim-
milk) containing culture fluid of the anti-ACE mAb 1D8, specific
to C domain [46–47]. Binding of mAb was detected using goat
anti-mouse HRP-conjugated antibody using the Immun star
WesternC
TM detection system (BIO-RAD, Hercules, CA). Chemi-
luminescence was detected with a chemiluminescence detector
(G:BOX Chemi, Syngene, Frederick, MD). Densitometry of
detected protein was performed using GeneTools software
(Syngene, Frederick, MD).
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immunoprecipitation assay)
96-well plates (Corning, Corning, NY) were coated with anti-
ACE mAbs via goat anti-mouse IgG (Pierce, Rockford, IL) bridge
[42] and incubated with samples of lysates from ACE- expressing
cells, representing membrane-bound form of ACE or culture
medium from these cells, representing soluble ACE secreted from
these cells, which were equilibrated for ACE activity with Hip-His-
Leu as a substrate. After washing of unbound ACE, plate-bound
ACE activity was measured by adding a substrate for ACE (Hip-
His-Leu) directly into wells [42].
Cell ELISA
Stable CHO-sACE expressing cell lines (sACE-A10) were
grown to confluency overnight in microtitre plates in enriched
medium. Once confluent, cells were incubated on ice with
blocking buffer (PBS with 2% skim milk) and then in the presence
of 10 mg/ml anti-ACE mAbs in the same buffer. Cells were fixed
with 4% paraformaldehyde and incubated in blocking buffer
containing a goat anti-mouse IgG HRP-conjugated antibody,
which was used to detect the amount of mAb bound to ACE
spectrophotometrically using a tetramethylbenzidine (TMB)
substrate.
MALDI-TOF MS analysis of mutant ACE-Y465D
Purified ACE-Y465D was resolved by SDS-PAGE and protein
detected by Coomassie stain. The sACE band was excised, cut into
1m m
2 pieces and destained with 200 mM NH4CO3:acetonitrile
(ACN) (50:50) until clear. Samples were dehydrated with 100%
ACN and dried on a Savant SpeedyVac (ThermoScientific,
Farmingdale, NY). Samples were sent to the Centre for Proteomic
and Genomic Research (CPGR, Cape Town, South Africa) for
further analysis. Briefly, samples were reduced with 5 mM Tris (2-
carboxyethyl) phosphine (TCEP) (Fluka-USA, Milwaukee, WI) in
100 mMNH4CO3 inthe dark for 30 minutesat roomtemperature.
Excess TCEP was removed and the gel slices dehydrated. Cysteine
protection was performed by carbamidomethylation with 100 mM
iodoacetamide (Sigma-Aldrich, St. Louis, MO) in 100 mM
NH4CO3 for 30 minutes at room temperature in the dark. The
gel slices were then dehydrated, washed with 50 mM NH4CO3 and
Figure 1. The rate of mutant ACE shedding. A,D. Cell-associated ACE activity. Lysates from thoroughly washed cell monolayers from 35 mm
culture dishes were prepared using Triton X-100 as detergent. Membrane-bound ACE activity was determined fluorimetrically with Z-Phe-His-Leu as a
substrate and expressed as the total mU in each sample and is the mean+SD of four experiments performed in du- or triplicates. B,E. Soluble
(secreted) ACE activity. The ACE activity in the culture medium of ACE expressing cells from which the cell pellets were used in part A, D was
determined fluorimetrically as above. C,F. Rate of ACE secretion. The rate of ACE cleavage was determined as the ratio between ACE in the culture
medium and the sum of cell-associated and secreted ACE. Data are expressed as a percentage from the mean of WT ACE.
doi:10.1371/journal.pone.0025952.g001
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thegelslicesintrypsinsolution (Promega,Madison,WI)toa 20 ng/
ml final concentration and incubating at 37uC overnight. Peptides
were extracted from the gel slices with 50 ml 0.1% trifluoroacetic
acid (TFA) (Sigma -Aldrich, St. Louis, MO). Samples were dried
down, resuspended in 50 mld H 2O and further dried down to 20 ml
to remove residual NH4CO3. Peptides were spotted onto a 10 mg/
ml a-cyano-4-hydroxycinmanic acid matrix (Fluka-USA, Milwau-
kee, WI) in 80% ACN, 0.2% TFA for a final concentration of
5 mg/ml matrix in 40% ACN, 0.1% TFA, 10 mM NH4H2PO4.
Mass spectrometrywas performed with a 4800 MALDI TOF/TOF
(Applied Biosystems, Foster City, CA) with all spectra recorded in
positive reflector mode. Spectra were generated with 400 laser
shots/spectrum at a laser intensity of 3800 (arbitrary units) with a
grid voltage of 16 kV. Peptides spots were internally calibrated with
trypsin autolytic fragments.
Molecular modeling of ACE
Analysis of the N domain was based on the recently published
crystal structure [38] (PDB accession number 3NXQ) and the C
domain was based on the structure resolved by Natesh et al. [48]
(PDB accession number 1O86). PYMOL (http://www.pymol.org)
was used to make the Y465D substitution in silico using the in-built
mutagenesis software. A model of complete human sACE was
constructed using the model of porcine sACE based on electron
microscopy (EM) [49] and visualized using Chimera [50].
Arrangement of X-ray 3D densities of the N and C domains
(PDB-IDs: 3NXQ_chain A and 1O86) into the porcine somatic
lung ACE electron microscope model was done (1) by alignment of
both domains’ N-termini to north and their C-termini accordingly
to south, along the longitudinal axis of the ACE-model, (2) by
setting the domains’ X-ray 3D densities to 2,3 nm resolution and
fitting them into the ACE-model semi-automatically with the ‘Fit
in map’ module, and (3) by shifting and rotating both domains
manually to re-align them to the models longitudinal axis and to
get the N-domain Glu590 residue proximal to the C-domain’s N-
terminus, giving it the optimal fit for the ‘hinge’ residues Val591 to
Gly610. The epitopes were marked on the N and C domains
according to [40,51–55] and two such ACE 3D models were
arranged back-to-back with both their N-domains, similar to the
dimer of human ACE (3NXQ). Structural figures were generated
in Chimera or PYMOL. Protein-protein interactions were iden-
tified using PDBSum [http://www.ebi.ac.uk/pdbsum/]. Analysis
of the effect of the mutation on residues involved in dimer
association was performed using PISA [56].
Results and Discussion
Identification of the novel ACE mutation
Certain individuals within a family demonstrated plasma ACE
levels 5- to 7-fold higher than normal (Nesterovitch et al. 2011, in
Figure 2. Western blot analysis of normal and mutant ACEs. A. The lysates and culture medium of HEK cells expressing WT and mutant
(Y465D) ACE (normalized by equal ACE activity loading 25 mU/ml) were subjected to SDS-PAGE (7.5% gel) in reducing conditions for Western
blotting with mAbs 3C5 and 5C8 recognizing different sequential epitopes on the C domain of ACE [45–47]. Proteins transferred on PVDF-Plus
membrane were revealed with 2 mg/ml of indicated mAb. Molecular weight markers are shown by arrows on the left of panel A, which is a
representative experiment. B. Revelation of WT and mutant ACE presented in panel A (with mAb 3C5) and with mAb 5C8 (not shown) was quantified
by densitometry of the bands. Data presented as a ratio of density with mAb 5C8 to that with mAb 3C5 by the image analysis (densitometry) using
ImageJ software (NIH). Data are expressed as mean 6 SD of 3 independent experiments. C. Western blot analysis was performed on total cell lysate
and concentrated medium from CHO cells transfected with WT and ACE-Y465D. Samples were separated by 6% SDS-PAGE in the presence (right)o r
absence (left) of 2-mercaptoethanol. Immunoblotting was performed and ACE was detected with the C domain-specific mAb 1D8 [47]. D.
Densitometric analysis of cell lysates separated by Western blot, calculated as the percentage dimer of monomer (D/M). Data is the mean 6 SD of
samples prepared in duplicate.
doi:10.1371/journal.pone.0025952.g002
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8 of the ACE gene, which is a T.G transition that converts codon
TAT (encoding Tyr at position 465 - mature somatic ACE
numbering [17]) to GAT (encoding Asp). No other mutation was
presentinACEgeneexonsfromthesesubjects,suggestinga possible
link between the high plasma ACE observed and the Y465D
mutation. Some of the carriers of this mutation demonstrated
symptoms of nausea, vomiting, fatigue, or depression. These might
be caused by changes in ACE hydrolysis of neuropeptides (ACE
substrates) or by ACE signaling (for example, via changes in ACE
dimerization) induced by ACE substrates or endogenous ACE
inhibitors; however, the etiology remains unclear.
The regulation of ACE shedding by the putative secretase is
likely to differ significantly in various cell types. ACE expression
levels are comparable in lung endothelial cells and in the epithelial
cells of the proximal tubules of the kidney and seminiferous tubules
[11,13,57]. However, the respective levels of soluble ACE in these
three compartments differ by 2500-fold, being highest in seminal
fluid, 50-fold less in the blood and further 50-fold decrease-in the
urine (data not shown). Thus, determining the effect of the Y465D
mutation on shedding and/or dimerization in different cell lines
could be more informative.
The elevated plasma ACE levels observed with the Y465D
substitution are likely due to: a) increased ACE expression in cells
Figure 3. Conformational fingerprint of mutant ACE. A–D. Precipitation of ACE activity from cell lysates (membrane-bound form) and culture
medium (soluble form) from HEK and CHO cells expressing WT and mutant (Y465D) ACE was estimated using 16 mAbs to the epitopes localized on
the N and C domains of human ACE. Samples were equilibrated according to 5 mU/ml of the ACE activity with Hip-His-Leu as a substrate and
incubated with a wells on the microtiter plate covered by mAbs to ACE via goat-anti-mouse IgG; then precipitated ACE activity was quantified by
fluorimetric assay - plate precipitation assay [42]. Data are expressed as a ratio of ACE activity precipitated by different mAbs from mutant ACE to that
of WT ACE. Data presented as a mean of 3–4 independent determinations in duplicate. * p,0.05 indicates ratio shown is significantly different from 1.
mAbs showing significant changes in binding compared to WT are colored (red: increase .20%, yellow: decrease .20%).
doi:10.1371/journal.pone.0025952.g003
Novel ACE Mutation (Y465D) Increases ACE Shedding
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25952or b) increased ectodomain shedding of ACE. To elucidate the
mechanism(s) involved in the elevation of plasma ACE in the
affected individuals, we performed site-directed mutagenesis of
human recombinant ACE, expressed this mutant in HEK and
CHO cells, and compared the biochemical and immunological
characteristics of this mutant with wild-type (WT) ACE.
Expression of Y465D in HEK and CHO cells
After stable expression of the Y465D mutant ACE (ACE-
Y465D) in HEK and CHO cells, we determined the enzymatic
activity of the soluble and membrane-bound forms, the rate of
shedding, and possible structural abnormalities of ACE-Y465D
compared to WT. ACE activity of the membrane-bound form of
ACE-Y465D was comparable with WT ACE. However, ACE-
Y465D activity in the culture medium and thus its rate of shedding
was 3- and 8-fold higher than WT in HEK and CHO cells,
respectively (Fig. 1). This occurred regardless of whether artificial
tripeptide substrates (HHL or ZPHL) or longer natural substrates
(substance P – data not shown) were used. Moreover, we also
tested the amount of immunoreactive ACE protein in the culture
medium using a plate immunoprecipitation assay [58]. For the
Y465D mutant, the amount of ACE protein and activity increased
to a similar extent (not shown). We also demonstrated that the
inhibition of mutant ACE by enalaprilat was similar to WT ACE
(not shown).
Western blot analysis was performed on total cell lysate and
medium harvested from HEK and CHO cells expressing WT and
ACE-Y465D to confirm that the mutation did not alter ACE
expression. The cell-associated WT and mutant ACE resolved at
approximately 180 kDa (Fig. 2A, C). The lower molecular weight
band in cell lysate likely represents a non-specific band as it was
observed in most lysates with different anti-ACE mAbs. A higher
molecular weight form .300 kDa was observed for both WT and
the ACE-Y465D [seen only in CHO cells expressing Y465D
(Fig. 2C,D) likely due to enrichment of ACE by flow cytometry]
consistent with a disulphide-mediated ACE dimer [39,55,59],
since this form is not observed in the presence of reducing agent.
Densitometric analysis of cell lysate indicated a 5-fold increase in
the ratio of dimer to monomer with ACE-Y465D (Fig. 2D), but
the formation of dimers was not consistently observed. This
reflects the limitations of determining dimer formation using SDS-
PAGE [59] and requires verification by other approaches. In both
cell associated and soluble forms, the mutant resolves slightly
higher than the WT, which could be the result of alterations in
post-translational processing such as glycosylation or phosphory-
lation due to accelerated shedding and/or accelerated trafficking
of ACE-Y465D to the cell membrane. These results suggest that
the mutation has no aberrant effect on ACE expression.
Therefore, the elevated plasma ACE levels observed in individuals
expressing the Y465D mutation are more likely to be the result of
changes in the ectodomain shedding than the result of increased
protein expression.
Immunological characterization of the ACE-Y465D
The 5-fold increase in shedding of the Pro1199Leu mutation
[32] demonstrates the role of juxtamembrane residues in the
Figure 4. Binding of mAbs to mutant ACE on the surface of CHO cells (Cell ELISA). Cell ELISA assay was performed on CHO cells expressing
WT and mutant (Y465D) ACE using the panel of 16 mAbs directed to different epitopes on the N- and C domains of human ACE. A. Binding of mAbs
to WT ACE determined via secondary Ab - anti-mouse IgG conjugated to peroxidase - optical density at 405 nm. Non-specific binding of the
secondary mAbs to control non-immune mouse IgG was subtracted. B. Data are expressed as a percentage of mAbs binding to surface of CHO cells
expressing mutant ACE to that expressing WT ACE and normalized for surface ACE expression. Data presented as a mean of 3–4 independent
determinations in duplicate. mAbs showing significant changes in binding compared to WT are colored (red- increase .20%, yellow-decrease .20%).
*p ,0.05 indicates ratio shown is significantly different from 1.
doi:10.1371/journal.pone.0025952.g004
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of the N domain Y465D mutation, distal to the stalk region, on
ectodomain shedding is intriguing. Moreover, the binding of two
mAbs (9B9 and 3A5) to overlapping epitopes on the N domain of
ACE results in a 2- to 4-fold increase in ACE shedding [60].
Therefore, conformational changes in the N domain of ACE,
induced by mAb binding, may lead to changes in conformation of
the stalk region or exposure of a sheddase recognition domain in
ACE distal to the stalk cleavage site [40,51,55].
To investigate the conformational changes induced by the
Y465D mutation, we performed conformational fingerprinting of
ACE using 16 mAbs to different epitopes on the N and C domains
[61]. Of particular interest were the mAbs whose interactions with
ACE are known to affect shedding, namely the N-domain specific
mAbs 9B9, 3G8 and 3A5 [40,51,55,60], and those whose epitopes
were occluded by the opposite domain. These include the epitopes
of mAbs 1G12 and 6A12 in the N domain [52] and mAbs 1E10,
2H9 and 4E3 in the C domain [54]. Multiple conformational
changes in the ACE molecule were observed as a result of this
single mutation (Fig. 3). Unlike previous single amino acid
mutations which only affected mAb binding to the specific epitope
where the mutation occurs, Y465D appears to affect binding of 12
mAbs to distal epitopes (Fig. 3A and C). Interestingly, the changes
in mAbs binding were much more prominent for the membrane-
bound form than for the soluble form of ACE (Fig. 3). We
demonstrated previously, by determining the conformational
fingerprint of ACE, that the ACE conformation differed
significantly between the soluble and membrane bound forms
[61]. The native conformation of ACE on the cell surface,
determined by cell ELISA, also differed significantly from soluble
form. In particular, the epitopes for mAbs 1B3, 1B8/3F10, and
1E10 were not exposed on native, catalytically active ACE
expressed on the surface of CHO cells [54]. Moreover, the kinetic
characteristics, including the domain specificity of some substrates,
differed significantly between solubilized ACE and ACE expressed
on the cell surface [62].
Cell ELISA using the panel of domain-specific anti-ACE mAbs
was performed on mutant and WT ACE expressed on the surface
of CHO cells (Fig. 4). Stable CHO-ACE cell lines (WT and
Y465D) were subjected to flow cytometry sorting to increase ACE
expression, and thus, to increase the sensitivity of the cell ELISA.
Binding of these 16 mAbs to surface WT ACE differs by more
than an order of magnitude, reflecting differences in affinity as well
as in exposure of the ACE epitopes for different mAbs (Fig. 4A).
The Y465D substitution significantly increased binding of 4 mAbs
(3A5, 1B3, 1E10 and 2H9) and decreased binding of mAb 5F1 and
6A12 (Fig. 4B).
There was a consistent loss of affinity for the N-domain specific
mAb 5F1 with cell-associated and soluble mutant ACE in the
precipitation assay (Fig. 3) as well as membrane-bound ACE-
Y465D in the cell ELISA (Fig. 4B). Y465 might participate directly
in mAb 5F1 binding to ACE, because it is localized close to/within
the epitope for mAb 5F1 [53] (Fig. 5), or the mutation has resulted
in gross conformational changes that have altered the mAb 5F1
epitope. Alternatively, the changes in putative ACE dimerization
have masked the epitope for mAb 5F1.
Similarly, a consistent increase in affinity for the C-domain
specific mAb 1B3 was observed across these experiments, the
epitope of which lies in the C-terminal region of the C domain,
including the stalk region (Fig. 5) [46,54]. It has been noted that
mAb 1B3 binding indicates rearrangement of the juxtamembrane
region [63] and an increase in binding of mAb 1B3 is consistent
with increased shedding. Rearrangement of the stalk region and
exposure of the cleavage site is most likely the cause of both the
increase in affinity for mAb 1B3, and/or greater accessibility of the
secretase, resulting in increased shedding.
Therefore, the alterations in the conformational fingerprint of
ACE, exposing some epitopes (9B9, 3A5, 1B3, 1B8/3F10, 1E10/
4E3, 2H9) and masking others (1G12/6A12, 5F1) were revealed
by the panel of domain-specific mAbs. These alterations, induced
by a single amino-acid mutation in the N domain, indicate
conformational changes of the ACE molecule, which might be due
to changes in the extent of ACE dimerization.
Induction and inhibition of mutant ACE shedding
In order to characterize the mechanism of mutant ACE
shedding further we tested known inducers and inhibitors of WT
ACE shedding on CHO and HEK cells expressing ACE-Y465D.
The effect of both stimulation of shedding by the phorbol esters,
PMA (HEK) or PDBu (CHO), and the serine protease inhibitor
DCI, as well as inhibition by hydroxamate-based inhibitors of
Figure 5. Epitope mapping of human sACE using EM-based
model. Model of human sACE was generated using an EM-based
model of porcine sACE [49]. Epitopes localization (colored spots) were
taken from the following publications [40,51–55].. Relevant amino acid
residues in the ectodomain and juxtamembrane region of ACE and a
cartoon of the membrane-bound ACE secretase are indicated: Leu1 and
Asp616-N terminal residues of the N- and C-domains, respectively;
Pro1193 –the last amino acid residues seen in the 3D structure of C
domain; Pro1199 – localization of P1199L mutation causing 5-fold
increase in blood ACE levels [32]; Arg1203-C-terminal amino acid
residue of soluble ACE [23]; Val1228-Ser1248-transmembrane domain
[65]; Ser1277-C-terminal amino acid residue of full-length somatic ACE
[17].
doi:10.1371/journal.pone.0025952.g005
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determined (Fig. 6). Phorbol ester induced basal shedding of
ACE-Y465D in CHO cells by approximately 4.5-fold, while DCI
caused a 5-fold increase in shedding in CHO cells (Fig. 6B) and
had no effect on ACE shedding in HEK cells (Fig. 6A). Shedding
was significantly inhibited in the presence of batimastat in HEK
cells and by TAPI in CHO cells. The different shedding profiles
between the two cell types expressing mutant ACE indicates that
our understanding of the complex mechanism of ACE shedding is
still incomplete. Furthermore, the regulation of ACE shedding
likely includes other putative ACE- or ACE secretase-binding
proteins whose expression in CHO and HEK cells could be very
different.
We also tested the ability of mAbs, known to induce ACE
shedding in WT ACE (mAbs 9B9 and 3A5 [40,51,55,60] on the
shedding of mutant ACE, expressed in HEK and CHO cells
(Fig. 6). The Y465D substitution abolished the mAb-induced
shedding observed with WT ACE on the surface of CHO and
HEK cells. This could mean that mutant ACE has already formed
the conformation sACE adopts upon binding of mAb 3A5, and
mAb 9B9 to a lesser extent, and thus re-sets the basal levels of
shedding by allowing better access of the secretase.
These results support the hypothesis that a mutation in the N
domain of ACE can induce conformational changes that increase
access of the ACE secretase, either through exposure of the stalk
region or of a recognition domain. This is indicated by the
increased affinity of C-domain specific mAbs 1E10 and 2H9 for
the membrane-bound form of mutant ACE (Fig. 4B). The epitopes
for these mAbs are located on the N-terminal region of the C
domain (Fig. 5) and previous findings indicate that they are
occluded by the N domain [54] and may form a conformation
similar to the compact structure proposed previously [64].
Increased interaction of these mAbs with mutant ACE (Y465D)
indicates that this region has become exposed, allowing for better
access of the mAbs, most likely due to movement of the N domain
as the protein moves into a more extended conformation. This is
further supported by the fact that regions distal to the proposed
domain interaction surface also seem to have undergone changes
since the anti-N domain mAbs 9B9, 3A5, 3G8 and i1A8 on CHO
cells bind the cell-associated mutant ACE with a higher affinity
and mAbs 9B9 and 3A5 on HEK cells bind soluble and
membrane-bound mutant ACE (mAb 3A5) better.
Cleavage site determination
A possible explanation for the striking increase in shedding
observed for ACE-Y465D as well as different effects of known
inducers and inhibitors of ACE shedding is that the mutation has
altered the interaction of the secretase with ACE causing aberrant
shedding, most likely at a novel cleavage site. To test this
hypothesis, the cleavage site of ACE-Y465D was determined by
MALDI MS/MS (Fig. 7, Table 1). A tryptic digest of purified
soluble ACE revealed a fragment (m/z 1689.81, expected m/z
1689.81), which corresponds to the C-terminal cleaved peptide
(L1190-R1203). The peptide, containing Y465D (Y459-R467) was
identified as an m/z 1314.58 fragment (expected m/z 1314.59),
confirming the presence of the mutation in the protein sequence.
From these results, it seems that the Y465D transition does not
affect the cleavage site of the ACE sheddase(s) and that cleavage
occurs by the same mechanism as WT ACE.
In silico analysis of the Y465D mutation in ACE
Our results convincingly demonstrate that a single amino-acid
substitution in the N domain of ACE leads to significantly
increased ACE shedding as the result of gross conformational
changes of the two domains of sACE, but do not explain the fine
mechanisms of how this may occur. Previously we demonstrated
Figure 6. Stimulation and inhibition of mutant (Y465D) shedding. A. HEK cells expressing WT and mutant (Y465D) ACE were incubated in
serum-free basal medium containing phorbol-12-myristate-13-acetate (PMA), 3,4-dichloroisocoumarin (DCI), the hydroxamic acid-based matrix
metalloprotease inhibitor, batimastat (BB-94) or with ACE mAbs (9B9 or 3A5) for 24 hours. B. CHO cells expressing WT and mutant (Y465D) ACE were
incubated in minimal medium containing phorbol 12,13-dibutyrate (PDBu), DCI, tumour necrosis factor-a protease inhibitor (TAPI) or with ACE mAbs
(9B9 or 3A5) for four hours. Shedding was calculated as described in Figure 1. Data is the mean 6 SD of two experiments performed in duplicate. A
two-way ANOVA was performed for untreated versus treated for each cell line and indicated as * p,0.01.
doi:10.1371/journal.pone.0025952.g006
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ACE, the cysteines were protected using iodoacetamide, and the total digest subjected to MALDI TOF/TOF using the matrix a-cyano-4-
hydroxycinmanic acid. Masses corresponding to predicted ACE peptides are labeled. The masses corresponding to peptide containing Y465D and the
C-terminal cleavage peptide are indicated in bold.
doi:10.1371/journal.pone.0025952.g007
Table 1. MALDI MS/MS analysis of sACE-Y465D after tryptic digest.
Residue no Expected mass [MH]
+ Observed mass [MH]
+ Peptide sequence identified by MS/MS
53–71 2190.70 2191.08
133–151 2121.03 2121.04
188–199 1416.61 1416.61
327–340 1753.76 1753.80
433–446 1724.92 1724.91
447–453 808.41 808.38
459–467 1314.59 1314.58 YNFDWWDLR
518–532 1807.81 1807.80
623–629 957.43 957.41
751–762 1623.76 1623.75
776–785 1176.64 1176.62
798–811 1697.77 1697.76
812–828 2117.15 2117.15
1055–1065 1524.69 1524.68
1068–1077 1186.60 1186.59
1174–1180 912.53 912.51
1190–1203 1689.81 1689.81 LGWPQYNWTPNSAR
Masses (m/z) corresponding to ACE peptides, the peptide containing Y465D (underlined) and the C-terminal peptide are indicated in bold.
doi:10.1371/journal.pone.0025952.t001
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as dimers [39], which was later confirmed for porcine and human
endothelial cells [59]. Moreover purified sACE as well as
truncated N domain, but not C domain, were able to form dimers
in reverse micelles [39]. Furthermore, analysis of the effect of
mAbs on the induction and inhibition of ACE shedding [60] and
on ACE dimerization in reverse micelles suggests a link between
ACE dimerization and shedding [39–40].
Figure 8. Dimer of N domain of ACE. The dimer of the N domain was shown based on the structure of the N domain with N-domain specific
inhibitor RXP407 [38] - PDB accession # 3NXQ. The interface between monomers A (cyan) and B (yellow) is highlighted in green and magenta. Y465 is
highlighted in red. N9, N45, N416, and N480 (glycosylation sites) are rendered in green.
doi:10.1371/journal.pone.0025952.g008
Table 2. Contact residues involved in hydrogen bonding at the interface of native and mutated ACE based on PISA analysis.
Native protein Single Mutation in chain A Double Mutation in chains A and B
Residue Distance[A ˚] Residue Residue Distance[A ˚] Residue Residue Distance[A ˚] Residue
B:TYR 465[OH] 2.65 A:ASP 462[OD1] B:GLN 444[OE1] 3.27 A:ARG 453[NH2] B:GLN 444[OE1] 3.27 A:ARG 453[NH2]
B:GLN 598[NE2] 3.41 A:ARG 479[O] B:TYR 597[OH] 3.12 A:ASN 460 [ND2] B:TYR 597[OH] 3.12 A:ASN 460 [ND2]
B:GLU 481[N] 2.93 A:PRO 595[O] B:PRO 595[O] 2.99 A:GLU 481[N] B:PRO 595[O] 2.99 A:GLU 481[N]
B:ASN 460[ND2] 3.12 A:TYR 597[OH] B:ARG 479[O] 3.45 A:GLN 598[NE2] B:ARG 479[O] 3.45 A:GLN 598[NE2]
B:GLN 444[0E1] 3.27 A:ARG 453[NH2] B:GLN 598[OE1] 3.25 A:HIS 600[NE2] B:GLN 598[OE1] 3.25 A:HIS 600[NE2]
B:TYR 597[OH] 3.12 A:ASN 460[ND2] B:TYR 465[OH] 2.65 A:ASP 462[OD1] B:GLN 598[NE2] 3.41 A:ARG 479[O]
B:ASP 462[OD1] 2.55 A:TYR 465[OH] B:GLN 598[NE2] 3.41 A:ARG 479[O] B:GLU 481[N] 2.93 A:PRO 595[O]
B:PRO 595[O] 2.99 A:GLU 481[N] B:GLU 481[N] 2.93 A:PRO 595[O] B:ASN 460[ND2] 3.12 A:TYR 597[OH]
B:ARG 479[O] 3.45 A:GLN 598[NE2] B:ASN 460[ND2] 3.12 A:TYR 597[OH]
B:GLN 598[OE1] 3.25 A:HIS 600[NE2]
The residue column gives the description of the chain, residue name, residue number and atom involved in hydrogen bonding. The distance column represents the
calculated distance between the two interacting atoms. Bonding with Y465 is marked by bold. It was observed that transition from the native to the single followed by
the double mutation results in systematic loss of H-bonding at the interface.
doi:10.1371/journal.pone.0025952.t002
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per asymmetric unit, interacting via an interface encompassing
helices a10 and a27 on both molecules (2C6N) [64]. Recently, a
minimally glycosylated N domain (Ndom389) co-crystallized with
the domain selective phosphinic inhibitor, RXP407, (3NXQ),
demonstrated a similar protein-protein interface involving helices
a10, a20 and a21 [38] where the two molecules associate as
mirror images with a C2 axis of symmetry. Analysis of the former
structure demonstrates the localization of Y465 on helix a21 of
both molecules within this interface (Figure 8). The similarity of
these interfaces in both crystal structures is suggestive of their
involvement in protein-protein interactions, such as dimerization,
in vivo. The most likely interface for dimerization of the N domain
and potential residues involved were identified using the protein
interfaces, surfaces and assemblies service (PISA) program [56]
and PDBsum [http://www.ebi.ac.uk/pdbsum/] and given in
Figure 9. Dimer interactions observed at the interface of N domain. A. X-ray model showing all the residues at the interface. The color
scheme is the same as in Fig. 8. Hydrogen bonds and non-covalent interactions between Y465 (red) and other residues are shown by dashed lines.
B. A schematic representation of the protein-protein interactions at the dimer interface identified by PDBSum [http://www.ebi.ac.uk/pdbsum/]. The
residues and their interactions are colored using the following notation: hydrogen bonds –blue+dashed lines, non-bonded contacts - dashed lines,
positive residues - blue, negative residues - red, neutral residues - green, proline residues - orange, aromatic residues – magenta. Y465 is involved in a
hydrogen bond with D462 and hydrophobic non-bonded interaction with F461.
doi:10.1371/journal.pone.0025952.g009
Table 3. Solvent accessible surface area [A ˚2] of the interface for each chain of N domains.
Native protein Single Mutation in chain A Double Mutation in chains A and B
Chain A Chain B Chain A Chain B Chain A Chain B
933.9 932.6 915.9 920 904.4 897.8
Y465D mutation in chain B results in steady decrease of solvent accessible surface area at the interface.
doi:10.1371/journal.pone.0025952.t003
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driven mostly by hydrogen bonds and non-bonded contacts at the
interface formed by helix a21 (nomenclature as in [64]) of both
molecules (Figure 9). Y465 forms a hydrogen bond with D462 and
a non-covalent interaction with the phenyl ring of F461. A
computational model suggests that substitution of Tyr465 with an
Asp results in a subsequent loss of hydrogen bonding and non-
covalent interactions with F461 (Table 2). Thus, the loss of
energetically important interactions in the interface may cause
conformational changes that alter dimer formation, subsequently
resulting in changes in ACE shedding, such as those observed in
this study.
In a model of an ACE homodimer attached to the cell
membrane and marked with the key epitopes, the monomers are
oriented as mirror images associating via the N domains, with the
C domain of each monomer accessible for interactions with the
cell membrane (Fig. 10). This model reflects the conformational
fingerprinting of sACE-Y465D where binding of mAbs to at least
three epitopes was affected, namely 5F1, 1G12/6A12, and 1E10.
In addition, if dimerization requires a gross change in conforma-
tion to allow for interaction of the N domains of each monomer,
the conformation of the terminal region of the C domain,
including epitopes 1B8/3F10 and 1B3, and the juxtamembrane
stalk region, beyond P1199 would be affected. Moreover, the
epitope of mAb 5F1 appears to be significantly masked by dimer
formation via the N domain which could explain the dramatic
decrease in 5F1 binding with both cell-associated and soluble
ACE-Y465D (Fig. 3) and mutant ACE expressed on the cell
surface (Fig. 4). Comparison of these observations with the
conformational fingerprint of mutant ACE (Fig. 3) and the results
of cell ELISA (Fig. 4) shows that the theoretical and experimental
results mostly agree, rendering the proposed dimer an acceptable
working model for further investigation.
Conclusions
In this study, we ascribed a 5–7-fold elevation of plasma ACE to
a novel ACE mutation in which the codon GAT, encoding Tyr465
in the N domain of ACE, is substituted in one allele by TAT
coding for Asp. The identification and characterization of this and
other [32,33] mutations that result in increased shedding of ACE
are of considerable clinical importance considering that a
genetically determined increase in plasma ACE may lead to false
diagnosis of sarcoidosis and, consequently, to unnecessary long-
term immunosuppressive treatment [34]. Levels of plasma ACE
appear to be affected in two ways: either through the regulation of
gene expression and genetically linked to loci in the promoter
region of the ACE gene and other genomic loci, or through
spontaneous alterations of the ACE gene itself as in the case of the
Tyr465Asp and Pro1199Leu mutations. The link between the
alteration in plasma ACE levels due to the Y465D mutation and
the symptoms of nausea, vomiting, pain, depression and/or fatigue
in affected individuals remains unclear. Particularly since this is the
first mutation described that is associated with adverse clinical
symptoms.
The main reason for the absence of clinical abnormalities in
these patients is that their tissue ACE, generally 10- to 30-fold
higher than blood ACE, remains unaltered and thus the overall
substrate hydrolysis does not change significantly. We hypothe-
sized that the reason why most members of this family with the
Y465D mutation (6 out of 7) have one or more of the above
symptoms is due to elevation of plasma substance P or other
neuropeptides shown to be involved in similar neuropathophysio-
logical disorders [Nesterovitch et al. 2011, in preparation]. There
are two possible mechanistic scenarios: firstly, symptomatic family
members could have an additional mutation in another gene
which is responsible for aberrant metabolism and/or processing of
neuropeptides. Secondly, the Y465D mutation could result in a
Figure 10. A putative model of an ACE dimer attached to cell membrane. The yellow and red ‘‘dumbbells’’ correspond to the EM model of
porcine ACE. ACE monomers A (red) and B (yellow) are oriented such that they form a ‘‘back-to-back’’ complex. The N domain is rendered grey, C
domain – beige.
doi:10.1371/journal.pone.0025952.g010
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substance P or similar and as yet unknown neuropeptides. We
demonstrated the rate of hydrolysis of artificial, synthetic
substrates Hip-His-Leu and Z-Phe-His-Leu was not changed due
to the Y465D substitution. However, these experiments were
carried out with soluble ACE proteolytically released from the
membrane and the conformation and kinetics of the soluble and
membrane-bound forms of ACE can differ significantly [61–62].
Thus, one cannot exclude the likelihood that one mutation of ACE
causes both elevated blood ACE due to increased ACE shedding,
and elevated levels of neuropeptide(s), such as substance P,
resulting in neuropathological symptoms.
In summary, we have identified a novel Y465D mutation that
results in dramatic elevation of serum ACE, and is associated with
adverse clinical symptoms. Since elevated plasma ACE is often
taken as a marker of disease activity such as in sarcoidosis and
Gaucher’s disease, it is important for clinicians and medical
scientists to be aware of the alternative genetic causes of elevated
blood ACE that may or may not be linked to disease.
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